Exploring the utility of organo-polyoxometalate hybrids to inhibit SOX transcription factors by Kamesh Narasimhan et al.
Narasimhan et al. Cell Regeneration 2014, 3:10
http://www.cellregenerationjournal.com/content/3/1/10SHORT REPORT Open AccessExploring the utility of organo-polyoxometalate
hybrids to inhibit SOX transcription factors
Kamesh Narasimhan1,2*, Kevin Micoine3, Emmanuel Lacôte3, Serge Thorimbert3, Edwin Cheung2,5,
Bernold Hasenknopf3,4* and Ralf Jauch2,6*Abstract
Background: SOX transcription factors constitute an attractive target class for intervention with small molecules as
they play a prominent role in the field of regenerative biomedicine and cancer biology. However, rationally
engineering specific inhibitors that interfere with transcription factor DNA interfaces continues to be a monumental
challenge in the field of transcription factor chemical biology. Polyoxometalates (POMs) are inorganic compounds
that were previously shown to target the high-mobility group (HMG) of SOX proteins at nanomolar concentrations.
In continuation of this work, we carried out an assessment of the selectivity of a panel of newly synthesized
organo-polyoxometalate hybrids in targeting different transcription factor families to enable the usage of
polyoxometalates as specific SOX transcription factor drugs.
Results: The residual DNA-binding activities of 15 different transcription factors were measured after treatment with
a panel of diverse polyoxometalates. Polyoxometalates belonging to the Dawson structural class were found to be
more potent inhibitors than the Keggin class. Further, organically modified Dawson polyoxometalates were found to
be the most potent in inhibiting transcription factor DNA binding activity. The size of the polyoxometalates and its
derivitization were found to be the key determinants of their potency.
Conclusion: Polyoxometalates are highly potent, nanomolar range inhibitors of the DNA binding activity of the
Sox-HMG family. However, binding assays involving a limited subset of structurally diverse polyoxometalates
revealed a low selectivity profile against different transcription factor families. Further progress in achieving selectivity
and deciphering structure-activity relationship of POMs require the identification of POM binding sites on transcription
factors using elaborate approaches like X-ray crystallography and multidimensional NMR. In summary, our report
reaffirms that transcription factors are challenging molecular architectures and that future polyoxometalate
chemistry must consider further modification strategies, to address the substantial challenges involved in
achieving target selectivity.Background
Transcription factors (TFs) with critical functions in
cancer and stem-cell biology are desirable targets for
small molecule inhibition [1,2]. In particular, members
of the SOX TF family were reported to drive cancer pro-
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article, unless otherwise stated.proteins that would have great potential to counteract
oncogenesis are presently not available. Some of the best
selling drugs approved by the FDA (Food and drug ad-
ministration) are in fact known to target TFs [5]. How-
ever, those drugs do not bind the DNA binding domains
(DBDs) of TFs because of their highly electrostatic nature,
the lack of binding pockets, and the structural dynamics
of TFs in the absence of DNA [6]. We hypothesized that
the negatively charged Polyoxometalates (POMs) provide
a suitable scaffold for targeting DBDs [7]. POMs are nano-
meter sized inorganic oxyanions comprising transition
metals belonging to Group 5 and 6 of the periodic table in
their highest oxidation states [8]. The metals are held to-
gether by oxygen atoms and often enclose one or morentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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common structural POM families of importance in the
field of biomedicine are the Keggin [XM12O40]
n-, and the
Dawson structure [X2M18O62]
n– where M is the transition
metal atom (typically tungsten or molybdenum), X is the
heteroatom (typically phosphorous) and n is the number
of ionic charges (Figure 1) [8].
A variety of biological effects of POMs are documented
[9-15], including antitumor activity [16-19]. More recently,
the effective inhibition of various unrelated enzymes has
also been reported [20-25]. We previously identified the
Dawson phosphomolybdate (D1Mo: K6 [P2Mo18O62]) as a
nanomolar inhibitor of the Sox2-HMG domain [7]. Al-
though this Dawson-POM was found to be a rather potent
inhibitor of SOX-DNA interaction, it exhibits only moder-
ate selectivity. To optimize selectivity we now build upon
this previous study and examined the potential of a larger
panel of POMs, including novel organo-hybrids, and an
expanded set of TFs.
Materials and methods
To assess the selectivity of a panel of POMs, residual
DNA binding activity experiments were carried out
using different members of the Sox family and structur-
ally unrelated TFs such as Pax6, REST, FoxA1 and AP-
2γ. The mouse REST Cys2His2 zinc finger protein and
the HMG domains of the Sox paralogs Sox4, 5, 6, 7, 8, 9,
10, 11, 17 and 18 were purified using previously pub-
lished protocols [26,27]. Full length human AP-2γ and
full length FoxA1 proteins were prepared as described
[28,29]. Prior to carrying out selectivity assays, a 20 μM
working stock of the polyoxometalates was created in a
100% DMSO solution. The buffer solution for the residual
DNA binding experiments had the final working compos-
ition of 10 mM Tris pH 8.0 and 100 mM KCl prepared
with molecular grade water. The final DMSO composition
in the binding buffer was maintained at 2% v/v in the se-
lectivity assays. Hence addition of 2% DMSO alone acts as
a negative control for the assay, as DMSO at 2% v/v does
not influence the TF-DNA complex and hence the re-
sidual DNA binding activity measurements. Sox2-HMG
domain was previously shown to be inhibited by the
Dawson POM D1Mo (K6 [P2Mo18O62]) at an IC50 of 98.6 ±
22.1 nM [7]. Using the IC50 of Sox2 inhibition by the un-
modified Dawson POM D1Mo (K6 [P2Mo18O62]) as a ref-
erence, all the different inhibitor compounds were added
at a concentration of 125 nM to 15 different preassembled
TF-DNA complexes. TF concentrations were chosen such
that ~ 70-90% of the FAM-labeled DNA was bound. The
residual DNA binding activities of TFs were then obtained
either by fluorescence anisotropy measurements or by
quantifying EMSAs (Electrophoretic Mobility Shift as-
says). The residual DNA binding activity is calculated with
reference to the fraction of the maximally bound TF-DNAcomplex in the presence of 2% DMSO alone (without
compound treatment) and is reported as a percentage of
the fraction of bound TF-DNA complex before and after
compound addition. Hence 0% residual binding activity
would correspond to maximum inhibition, while 100%
activity would correspond to no inhibition. For Pax6, re-
sidual DNA binding activity was measured by EMSA
(Additional file 1: Figure S1) under the same condition
as the fluorescence anisotropy measurements, as Pax6
did not exhibit a significant change in anisotropy values
upon complex formation. The final reported residual
DNA binding activity is an average of five independent
experiments.






TTGCT-3’, where RE1, HPSE, FoxA1, Pax and CCND1
elements contain cognate binding sites of REST, AP-2γ,
FoxA1, Pax6 and Sox-HMG proteins respectively. La-
beled reverse complementary strands of the above se-
quences were used to generate DNA duplexes.
Sodium phosphomolybdate Na3 [PMo12O40], Sodium
phosphotungstate Na3 [PW12O40] and Sodium metatung-
state Na6W12O39 · xH2O were purchased from Sigma-
Aldrich. The general synthesis and ligation procedures of
organic substrates to Dawson POMs are outlined elsewhere
[30,31]. Bulk amounts of Dawson phosphomolybdate K6
[P2Mo18O62] were also obtained by custom synthesis from
Asischem Inc.
Results and discussions
In total, the residual DNA binding activities of 15 differ-
ent TFs were estimated against a panel of inhibitors that
could be broadly classified into “Keggin”, “Dawson” and
“simpler polyanion” (metatungstate, sodium molybdate
and decavanadate) types. The structures, compound acro-
nyms and the chemical formulas of POMs employed in
this study are given in Figure 1 and Table 1. The mean re-
sidual DNA binding activity of TFs from five independ-
ent experiments is displayed as a heatmap after hierarchical
clustering analysis using the “R heatmap.2” package
(Figure 2) [32].
The Dawson POMs were found to be highly potent in
their inhibition profiles of not only the Sox-HMG mem-
bers but also other TF families like FoxA1, REST and
AP2 (Additional file 2: Table S1). The simpler polyanion,
sodium molybdate serves the purpose of being an exter-
nal negative control in our assay and does not cause in-
hibition of any TF DNA complex. Overall, among the
TFs tested it was observed that Pax6 was the most inert
to treatment with POMs. The only POMs that were
Figure 1 The panel of polyoxometalates used in this study. Compound acronyms and the chemical formulas are as provided in Table 1.
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Table 1 Panel of inhibitor compounds screened for inhibition of DNA binding activity of 15 transcription factors
POMs Chemical formula Type Organic side chain Mol.wt
D1Mo K6 [P2Mo18O62] Dawson None 3016
D1W K6 [P2W18O62] Dawson None 4597
D2 (NC16H36)7 α1-[P2W17O62SnC6H8N4] Dawson Aliphatic 6089
D3 (NC16H36)7 α2-[P2W17O62SnC16H23N3O2] Dawson Val-Val-Val 6357
D4 (NC16H36)7 α2-[P2W17O62SnC6H11N4O] Dawson Aliphatic 6135
D5 (NC16H36)6 α2-[P2W17O61SnC4H10] Dawson Aliphatic 5794
D6 (NC16H36)6 α2-[P2W17O62SnC3H4O2] Dawson Aliphatic 5810
D7 (NC16H36)7 α1-[P2W17O66SnC24H34N4] Dawson Trp-Ala-Leu 6438
D8 (NC16H36)7 α1-[P2W17O66SnC22H32] Dawson Phe-Ala-Leu 6356
D9 (NC16H36)6 α1-[P2W17O61SnC4H10] Dawson Aliphatic 5794
D10 (NC16H36)7 α2-[P2W17O62SnC6H8N4] Dawson Aliphatic 6089
K1Mo Na3 [PMo12O40] Keggin None 1892
K1W Na3 [PW12O40] Keggin None 2946
decaV (NC16H36)3 [H3V10O28] Decavandate None 1688
metaW Na6W12O39 · xH2O Sodium metatungstate None 2969
MoO4
2− Na2MoO4 · 2H2O Sodium Molybdate None 206
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D4 and K1W (Figure 2). From the clustering analysis it
could be observed that the Keggin and Dawson POMs
exhibit a marked dichotomy in their selectivity and in-
hibition potential of TFs. Keggin POMs exhibit relatively
lower inhibition potency as compared to the Dawson
POMs on all TF families studied, suggesting that the size
or charge of POMs is an important consideration in the
inhibition of TFs (Figure 2). Keggin ions are almost spher-
ical and about 1 nm in diameter with 3– charge, whereas
Dawson ions are close to an elongated cylinder of about
1.5 × 1 nm with 6– or 7– charge. Metatungstate has the
size and shape of the Keggin ion, but a 6– charge similar
to the Dawson ion. Its high inhibition effect in the same
range as the Dawson POMs tends to privilege charge as
the discriminating factor for inhibition. The organically
modified Dawson POMs slightly amplified the inhibi-
tory potency of the unmodified Dawson scaffold D1W
(K6 [P2W18O62]). The side chain increases the steric bulk
and the substitution of a {WO}4+ by a {SnR}3+ fragment
also increases the negative charge of the framework.
Taken together, we surmise that a good POM inhibitor
must be at least 1 nm in diameter and should carry a
charge of 6– or more. This is consistent with previous
observations, but a larger panel of POMs must be
screened before a definite conclusion can be reached [10].
In any case, some caution should remain for structure-
activity relationships because POMs undergo hydroly-
sis and condensation reactions in water, and the proteins
might influence these equilibria. We believe that this
phenomenon is responsible for the behavior of the Dawson
molybdate (D1Mo: K6 [P2Mo18O62]) and the decavanadate(decaV). These compounds are known to be hydrolyti-
cally very unstable at neutral pH and inhibition is only
observed with a protein-dependent stabilization of the ac-
tive form [23].
Modified organic Dawson POMs were tested under
the assumption that their organic side-chains would be
capable of enabling selective inhibition, however the out-
come of testing a limited sub-set of modified Dawson
POMs indicates substantial challenges involved in achiev-
ing selectivity against different TF DNA binding domains.
The modified Dawson POMs showed amplified potency
without exhibiting selectivity between various TFs. The
amplified potency of the modified Dawson POMs when
compared to the unmodified Dawson POM is presumably
due to size and charge effects as discussed above. Interac-
tions of the organic side chains with TFs might further-
more occur, but are not sufficiently discriminating here.
Further progress in this regard, requires the identification
of the Dawson POM binding sites on the Sox-HMG do-
main by higher resolution techniques like X-ray crystallog-
raphy and multi-dimensional NMR, before optimally
designed organic side chains can be grafted onto the inor-
ganic scaffold.
Even though targeting the DNA binding domains of
TFs is challenging, evolving a core inhibitor scaffold that
can be functionally customized to achieve specificity will
have a significant impact in developing drugs that target
TFs. Recent advancements in click chemistry to incorpor-
ate a range of organic substrates in tin substituted Dawson
POMs has expanded the horizon of organic modifications
that could be achieved in POM chemistry [30,31]. We



















































































Figure 2 (See legend on next page.)
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Figure 2 A heatmap displaying the average residual DNA binding activities of 15 different TFs upon treatment with 125 nM of a panel
of inhibitor compounds. The residual DNA binding activity is reported as an average of five independent experiments. Two-dimensional
clustering of the residual DNA binding activities was carried out by hierarchical clustering analysis (Euclidean distance). (Red color indicates
high inhibition, while yellow color indicates relatively lesser inhibition). Inhibitor compounds are color coded by their POM class. Inset shows typical
inhibition profiles of representative TFs namely Sox17, REST and Pax6 upon treatment with Dawson POM K6 [P2Mo18O62] (D1Mo), measured by
fluorescence anisotropy.
Narasimhan et al. Cell Regeneration 2014, 3:10 Page 6 of 7
http://www.cellregenerationjournal.com/content/3/1/10provides a powerful strategy and that target selectivity
could be achieved by conjugation with natural biological
molecules like carbohydrates, steroids and peptides. It can
be envisaged that in the future, subsets of TF interaction
domains or even whole peptides conjugated with synthetic
Dawson POMs will spawn the development of a newer
breed of POMs that can be eventually tested for targeting
regulatory or DNA binding domains in a truly selective
way.
The selectivity assay described thus far has been car-
ried out in vitro using short DNA molecules and isolated
DNA binding domains at a non-neutral pH (pH 8.0).
Any conclusive assessment and future development of
synthetic Dawson POMs also requires that these experi-
ments be extended further onto cell-lines and animal
models where a multitude of variables like protein co-
factor interactions, salinity and pH will affect the final
drug response. In this regard, it has been noted that
POMs are large and highly negatively charged rendering
their penetration of cellular membranes a serious chal-
lenge [33]. However, several advancements like encapsu-
lation of POMs in liposomes have been achieved to
overcome this challenge of delivery into cells [33]. Over-
all, the results shown here reaffirms that transcription
factors are indeed challenging molecular architectures
and that polyoxometalate platforms like the Dawson
phosphotungstate which combine inhibition potency and
easy chemical modification should be further systematic-
ally explored to truly achieve target selectivity.Additional files
Additional file 1: Figure S1. The inhibition of Pax6 by a panel of
inhibitor compounds studied using EMSA. Residual DNA binding
activity was estimated from maximally bound Pax6-DNA (no POM,
2% DMSO) and free DNA gel-shift intensities (Pax6 DNA alone) as
reference.
Additional file 2: Table S1. Residual DNA binding activities (in %) of 15
TFs upon treatment with a panel of inhibitors. The residual DNA binding
activity is expressed as mean ± relative standard deviation from five
independent experiments.
Abbreviation
POMs: Polyoxometalates; TFs: Transcription factors; DBD: DNA binding
domain; EMSA: Electrophoretic Mobility Shift assay.
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